| Features | OFLOTUB Trial (N = 1692) | RAFA trial (N = 780) | |||
| Gatifloxacin arm (n = 848) | Control arm (n = 844) | Arm A (n = 263) | Arm B (n = 258) | Arm C (n = 259) | |
| Country, n (%) |
|
|
|
|
|
| South Africa | 191 (22.5) | 181 (21.4) | N/A | N/A | N/A |
| Benin | 158 (18.6) | 158 (18.7) | 71 (27.0) | 71 (27.5) | 70 (27.0) |
| Guinea | 221 (26.1) | 225 (26.7) | 158 (60.1) | 157 (60.9) | 155 (59.8) |
| Kenya | 100 (11.8) | 100 (11.8) | N/A | N/A | N/A |
| Senegal | 178 (21.0) | 180 (21.3) | 34 (12.9) | 30 (11.6) | 34 (13.1) |
| Age (Years) |
|
|
|
|
|
| Mean ± SD | 30.9 ± 9.1 | 30.6 ± 9.0 | 36.4±9.2 | 36.5±10.1 | 35.9 ± 9.7 |
| Female sex | 229 | 233 | 129 | 112 | 118 |
| BMI (kg/m2) |
|
|
|
|
|
| Mean ± SD | 17.4 ± 4.9 | 17.5 ± 5.0 | 18.2 ± 3.1 | 17.7 ± 2.9 | 18.4 ± 2.6 |